•
Don’t Monkey Around With Monkeypox
Talks about Medicine, Monkeypox and Monkeypox Virus
DE
David Epstein
Past Chief Executive Officer Seagen
Miami-Fort Lauderdale Area
Overview
David Epstein is currently the Chief Executive Officer at Seagen, with a background in the pharmaceutical industry and expertise in oncology, biotechnology, and healthcare. His notable career highlights include serving as Chairman at Agomab and holding board positions at various companies such as Tempus AI and Cellestia Biotech.
Work Experience
Chairman & CEO
2024 - Current
Chairman
2024
Board Member
2024
Board Member
2020
Pelican Harbor Seabird Station is a Center for Seabird Rehabilitation.
Board Member
2019
Valo Health is a technology company focused on utilizing large scale data and AI-driven computation to discover and develop therapeutics.
Raised $460,000,000.00 from HBM Healthcare Investments.
Managing General Partner
2016
Consulting and Board Services
Board Member
2024 - 2025
A biotechnology company developing RNA technologies to shape the future of gene therapy
Raised $147,500,000.00 from New Enterprise Associates, Decheng Capital, Mission BioCapital, Breton Capital Management, Ling Wong and Willett Advisors LLC.
Chief Executive Officer
2022 - 2023
Company sold
Seagen is a clinical-stage biotechnology company dedicated to improving patient outcomes with advanced antibody-drug conjugate technology.
Raised $2,219,000,000.00 from Merck, Takeda and New Enterprise Associates.
Independent Director
2022 - 2023
Independent Director
2020 - 2023